What the studies show
The licensed indication: glucagon raises blood glucose within minutes by mobilising hepatic glycogen, and is the standard rescue treatment when someone with diabetes cannot take sugar by mouth. The effect is large, fast and uncontested.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Gvoke (glucagon injection) prescribing information.DailyMed, read 29 Oct 2026Route, half-life and licensed use of the ready-to-use subcutaneous injection.
- 2Baqsimi (glucagon nasal powder) prescribing information.DailyMed, read 29 Oct 2026Nasal route; median half-life about 35 minutes.
In context
Glucagon is the 29-amino-acid pancreatic hormone that mobilises stored glucose from the liver, and the emergency treatment for severe hypoglycaemia in people with diabetes. Modern formulations removed the reconstitution step that made the old kits hard to use in a crisis: a ready-to-use injection and a nasal powder. In a 75-person crossover trial the nasal powder raised blood glucose successfully at all but one dosing visit, against all visits for intramuscular injection. It is prescription-only everywhere LYO covers.
Glucagon is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Glucagon proven to help with reversal of severe hypoglycaemia?
What studies are behind the grade?
Is Glucagon approved for this?
Other outcomes for Glucagon
- ANasal versus intramuscular delivery1 randomised crossover trial (n=75)
- ANausea and local discomfortadverse1 randomised crossover trial (n=75); approval programme
- DUse for weight loss or body compositionNone
Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →